HCA Midwest Health

Kansas City, Missouri 64132

1 studies enrolling now · 8 studies all time

What they study most

Advanced Renal Cell Carcinoma, Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification, Locally Advanced or Metastatic Breast Cancer, Metastatic Breast Cancer, Metastatic Renal Cell Carcinoma, Metastatic gpNMB Over-expressing Triple Negative Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Triple-Negative Breast Cancer

Studies at this site

• A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer — Recruiting now
• A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) — Completed
• Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation — Completed
• A Study of TAS-120 in Patients With Metastatic Breast Cancer — Stopped early
• A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) — Completed
• CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma — Completed
• Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC — Stopped early
• Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer — Completed